Every parliamentary written question tabled by Joshua Reynolds this session, with the full answer and department. See how every department answers, or back to the MP page.
Showing 461–464 of 464 · this parliament
What steps he is taking to improve the water quality of rivers.
After 14 years of Conservative failure, we share the public’s fury at the levels of sewage being released into our rivers, lakes and seas.That is why this Government has introduced legislation to put the water companies under special measures to end their...
Food and Rural Affairs, if he will make an assessment of the potential impact of proposed increases to water bills by Thames Water in the period to 2030 on households in relative poverty.
We understand the financial pressures hardworking families are currently facing, especially as many people have been impacted by cost-of-living challenges. Firmer action should have been taken over the last fourteen years to ensure money was spent on fixi...
Communities and Local Government, with reference to her Department's report entitled The impact of a change in the maximum park home sale commission, published on 16 June 2022, whether her Department has taken steps to review the efficacy of local authority enforcement for parks; and whether she plans to introduce a national enforcement body.
I refer the Hon Member to the answer I gave to Question UIN 1177 on 31 July 2024.
If he will make an assessment of the potential merits of providing access to Enhertu on the NHS for cancer patients.
Decisions on whether new medicines should be routinely funded by the NHS in England are taken by the National Institute for Health and Care Excellence (NICE) on the basis of an evaluation of a treatment’s costs and benefits. NICE’s methods are internationally respected, and have been developed through extensive work with industry, academics and the public to ensure they appropriately capture the costs and benefits, and best reflect social values. These are very difficult decisions to make, and it is important that they are made independently and on the basis of the available evidence. We understand that despite NICE instigating an exceptional pause in the process to allow for commercial negotiations to take place with the companies, Daiichi Sankyo and AstraZeneca, a deal to enable patient access to this treatment on the National Health Service in England has not been reached. We know NICE’s announcement has come as a blow to many women and their families. We understand that NICE and NHS England have already sought to apply as much flexibility as they can in their considerations of Enhertu for HER2 LOW breast cancer and have made it clear to the companies that their pricing of the drug remains the main obstacle to access. Within 16 weeks of the publication of final guidance, companies can also request a rapid review to consider new patient access scheme proposals, with the aim of establishing a pricing agreement that would improve cost-effectiveness and enable patient access to high-cost medicines. This Government wants to see a deal reached to make Enhertu available. NICE and NHS England remain open to considering an improved offer from the companies through the rapid review process, and we strongly encourage the companies to come back to the table.